Role of combination therapy in the treatment of hypertension: Focus on valsartan plus amlodipine

Advances in Therapy

Volumn 25, Issue 4, 2008, Pages 300-320

  Ferri, Claudio ^a   Croce, Giuseppe ^a   Desideri, Giovambattista ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Amlodipine; Angiotensin receptor antagonists; Angiotensin converting enzyme inhibitors; Dihydropyridine calcium channel antagonists; Hypertension; Treatment; Valsartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LOSARTAN; PLACEBO; THIAZIDE DIURETIC AGENT; VALSARTAN; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ATTITUDE TO HEALTH; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; LIFESTYLE MODIFICATION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; DRUG COMBINATION; LIFESTYLE;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; LIFE STYLE; TETRAZOLES; VALINE;

EID: 58149357532     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0042-x     Document Type: Review

References (58)

1. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
2. Cheung BM, Ong KL, Man YB, Lam KS, Lau CP. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens. 2006;8:93-98.
3. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363-2369.
4. Volpe M, Tocci G, Trimarco B, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens. 2007;25:1491-1498.
5. Weycker D, Nichols GA, O'Keeffe-Rosetti M, et al. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens. 2007;20:599-607.
6. Kindermann M, Adam O, Werner N, Böhm M. Clinical Trial Updates and Hotline Sessions. Presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol. 2007;96:767-786.
7. Elmer PJ, Obarzanek E, Vollmer WM, et al. PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med. 2006;144:485-495.
8. Lien LF, Brown AJ, Ard JD, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension. 2007;50:609-616.
9. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:345-351.
10. Guthrie B, Inkster M, Fahey T. Tackling therapeutic inertia: Role of treatment data in quality indicators. BMJ. 2007;335:542-544.
11. Basile J, Black HR, Flack JM, Izzo JL Jr. The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertension. J Clin Hypertens. 2007;9:636-645.
12. Fahey T, Schroeder K, Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: A systematic review. Br J Gen Pract. 2005;55:875-882.
13. Nesbitt SD. Antihypertensive combination therapy: Optimizing blood pressure control and cardiovascular risk reduction J Clin Hypertens. 2007;9(suppl 4):26-32.
14. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. FEVER Study Group. The Felodipine Event Reduction (FEVER) study: A randomized long-term placebocontrolled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157-2172.
15. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-840.
16. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
17. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
18. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension. European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
19. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
20. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation. 2002;106:672-678.
21. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
22. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
23. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
24. Mochizuki S, Dahlo7die;f B, Shimizu M, et al. Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (JIKEI heart study): A randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369:1431-1439.
25. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallelgroup studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563-580.
26. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther. 2003;1:43-50.
27. Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebocontrolled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61-73.
28. Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R. COmparative Study of efficacy of Irbesartan/HCTZ with valsartan/HCTZ using home blood pressure Monitoring in the treAtment of mild-to-moderate hypertension (COSIMA) Investigators. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens. 2005;18:1482-1488.
29. Neutel JM, Saunders E, Bakris GL, et al. INCLUSIVE Investigators. The efficacy and safety of low-and highdose fixed combinations of irbesartan/ hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: The INCLUSIVE trial. Clin Hypertens. 2005;7:578-586.
30. Julius S, Kjeldsen SE, Weber M, et al. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022-2031.
31. Kjeldsen SE, Julius S, Mancia G, et al. VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: The VALUE trial. J Hypertens. 2006;24:1405-1412.
32. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension. 2007;50:467-473.
33. Voors AA. Vascular benefits of angiotensin receptor blockers. Expert Opin Investig Drugs. 2007;16:987-997.
34. Lu HK, Fern RJ, Luthin D, et al. Angiotensin II stimulates T-type Ca2+ channel currents via activation of a G protein, Gi. Am J Physiol. 1996;271:C1340-C1349.
35. Desideri G, Bravi MC, Tucci M, et al. Angiotensin II inhibits endothelial cell motility through an AT1-dependent oxidant-sensitive decrement of nitric oxide availability. Arterioscler Thromb Vasc Biol. 2003;23:1218-1223.
36. Neusser M, Tepel M, Golinski P, et al. Different calcium storage pools in vascular smooth muscle cells from spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertens. 1994;12:533-538.
37. Carraro-Lacroix LR, Malnic G. Signaling pathways involved with the stimulatory effect of angiotensin II on vacuolar H+-ATPase in proximal tubule cells. Pflugers Arch. 2006;452:728-736.
38. Fuller AJ, Hauschild BC, Gonzalez-Villalobos R, et al. Calcium and chloride channel activation by angiotensin II-AT1 receptors in preglomerular vascular smooth muscle cells. Am J Physiol Renal Physiol. 2005;289:F760-F767.
39. Arun KH, Kaul CL, Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res. 2005;65:374-386.
40. de Champlain J, Karas M, Assouline L, et al. Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. J Clin Hypertens. 2007;9:168-178.
41. Batenburg WW, van Esch JH, Garrelds IM, et al. Carvedilol-induced antagonismof angiotensin II: A matter of alpha1-adrenoceptor blockade. J Hypertens. 2006;24:1355-1363.
42. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29:279-289.
43. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
44. Swales P, Williams B. Calcium channel blockade in combination with angiotensinconverting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension. J Renin Angiotensin Aldosterone Syst. 2002;3:79-89.
45. Kuschnir E, Acuña E, Sevilla D, et al. Treatment of patients with essential hypertension: Amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther. 1996;18:1213-1224.
46. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86:1182-1187.
47. Fogari R, Malamani GD, Zoppi A, et al. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2003;17:207-212.
48. Pedrinelli R, Dell'Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg oedema in essential hypertension. Hypertension. 2000;35:621-625.
49. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220-224.
50. Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation. 1999;100:1646-1652.
51. Williams SA, Rayman G, Tooke JE. Dependent oedema and attenuation of postural vasoconstriction associated with nifedipine therapy for hypertension in diabetic patients. Eur J Clin Pharmacol. 1989;37:333-335.
52. Iabichella ML, Dell'Omo G, Melillo E, Pedrinelli R. Calcium channel blockers blunt postural cutaneous vasoconstriction in hypertensive patients. Hypertension. 1997;29:931-937.
53. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet. 2007;369:201-207.
54. Atkins CE, Rausch WP, Gardner SY, Defrancesco TC, Keene BW, Levine JF. The effect of amlodipine and the combination of amlodipine and enalapril on the reninangiotensin-aldosterone system in the dog. J Vet Pharmacol Ther. 2007;30:394-400.
55. Ohbayashi Y, Tsutamoto T, Sakaguchi T, et al. Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: Comparison with a longacting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol. 2003;42(suppl 1):S71-S74.
56. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A metaanalysis. Am J Med. 2007;120:713-719.
57. Malacco E, Ferri C, Grandi AM, Kilama MO, Soglian AG, Vigna L. Treatment of hypertension and adherence to treatment guidelines in clinical practice: An Italian study. Adv Ther. 2005;22:96-106.
58. Wang J, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: A quantitative overview. Hypertension. 2007;50:151-158.